Endo Pharmaceuticals Solutions Inc. – ‘10-K405’ for 9/30/95 – EX-4

On:  Thursday, 12/28/95, at 11:38am ET   ·   For:  9/30/95   ·   Accession #:  948027-95-32   ·   File #s:  0-18728, 1-10430   ·   Correction:  This Filing was Corrected by the SEC on 3/18/96. ®

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report — [x] Reg. S-K Item 405   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K405     Annual Report -- [x] Reg. S-K Item 405                73    334K 
 2: EX-1        Underwriting Agreement                                18     80K 
 3: EX-2        Plan of Acquisition, Reorganization, Arrangement,     14     49K 
                          Liquidation or Succession                              
 4: EX-3        Articles of Incorporation/Organization or By-Laws      6     21K 
 5: EX-4        Instrument Defining the Rights of Security Holders     2     11K 
 6: EX-5        Opinion re: Legality                                  25     79K 
 7: EX-6        Opinion re: Discount on Capital Shares                19     66K 
 8: EX-7        Opinion re: Liquidation Preference                     1      5K 
 9: EX-8        Opinion re: Tax Matters                                1      7K 
10: EX-27       Financial Data Schedule (Pre-XBRL)                     1      8K 

EX-4   —   Instrument Defining the Rights of Security Holders

EX-4
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
October 30, 1995                                                   Ex. 10.44(a) 

Mr. Lewis D. Lepene                                                             
Vice President - Business Development                                           
Interneuron Pharmaceuticals, Inc.                                               
One Ledgemont Center                                                            
99 Hayden Avenue, Suite 340                                                     
Lexington, MA  02173                                                            

Dear Lew:                                                                       

This letter shall confirm the understanding we reached in our September 19, 1995
meeting regarding the choline sports drink. In that meeting, Veryfine and       
Interneuron agreed to enter a transitional phase in their relationship. This    
phase will involve the transfer of materials and information from Veryfine to   
Interneuron covering Veryfine's research of the sports drink market and         
approaches to launch the choline sports drink and provide the opportunity to    
exchange ideas on these matters. These steps are taken with the objective of an 
orderly transition of marketing and sales responsibility from Veryfine to       
Interneuron.                                                                    

Upon the successful conclusion to this transitional phase, but no later than    
ninety days from the date of this letter, Veryfine and Interneuron agree to     
terminate the current license agreement (the Patent and Know-How License        
Agreement between Interneuron Pharmaceuticals, Inc. and Veryfine Products, Inc. 
for Choline Sports Drink dated October 29, 1992, as amended). Upon termination, 
Veryfine and Interneuron agree that each do not and shall not have any          
obligations or liabilities to each other. Interneuron shall be free to enter    
license agreements with other companies and Veryfine shall have no further      
obligations to market and sell the choline sports drink. Interneuron and        
Veryfine agree that any public comment on this understanding, including but not 
limited to press releases, must be approved by both parties, such approval not  
to be unreasonably withheld or delayed.                                         

Veryfine and Interneuron remain interested in the possibility of working        
together in the future, either on the choline sports drink when it is launched  
as a liquid beverage in the mass market or other beverage products that         
Interneuron or its subsidiary, InterNutria, may wish to introduce.              

EX-4
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Mr. Lewis D. Lepene                                                             
October 30, 1995                                                                
Page 2                                                                          

If this letter reflects your understanding of the agreement reached in our last 
meeting, please sign where indicated below and return a copy to me. We wish you 
success with the choline sports drink and look forward to discussing other      
opportunities with you in the future.                                           

Sincerely,                                                                      

By:      /S/ AL CAROSI                                                          
Al Carosi                                                     
Vice President Marketing                                      

Agreed To By:       /S/ LEWIS D. LEPENE                                         
Signature                               

PRESIDENT & CEO, INTERNUTRIA, INC.      
Title                                   

NOVEMBER 7, 1995                        
Date                                    

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘10-K405’ Filing		Date		First		Last			Other Filings
Corrected on:		3/18/96							10-C
Filed on:		12/28/95
		11/7/95		2
		10/30/95		1		2
For Period End:		9/30/95							10-K/A,  DEF 14A
		9/19/95		1
		10/29/92		1
									List all Filings